Jul 6, 2015
1) Switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Ludwig Kappos about his paper on switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis. Dr. Sarah Wesley is reading our e-Pearl of the week about dopamine-responsive dystonia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Timothy Pedley about his Presidential Lecture at the AAN Meeting about the topics of neurologists' burnout, cost and quality of healthcare, value of neurology to congress and payers along with maintenance of certification. The participants had nothing to disclose except Drs. Keegan, Kappos, Wesley, Espay and Pedley.Dr. Keegan serves as Chief Editor of eMedicine; serves as an editorial board member of Multiple Sclerosis and Related Disorders; is a consultant for Novartis, Bristol-Meyers Squibb, Bionest Partners and receives research support from Terumo BCT and Caridian BCT.Dr. Kappos serves as an editorial board member of Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders and Journal of Neurology; receives research support from Actelion Pharmaceuticals Ltd, Addex, Bayer Schering Pharma, Biogen Idec, Biotica, CSL Behring, Genzyme Corporation, Eli Lilly and Company, Merck Serono, Mitsubishi, Novartis, Ono Pharma, Pfizer Inc, Receptos, Roche, Sanofi-aventis, Santhera, Siemens, Teva Pharmaceutical Industries Ltd., UCB, Xenoport, Swiss National Research Foundation and the European Union and The Swiss MS Society; honoraria and other payments for all these activities have been exclusively used for funding of research of his department.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Pedley serves as an editorial board member of Journal of Clinical Neurophysiology and Nature Reviews Neurology and as Editor-in-Chief (Neurology) for UpToDate; serves as President for the American Academy of Neurology; receives royalties form the publication of the books Current Practice of Clinical Electroencephalography, Epilepsy: A comprehensive Textbook and Merritt's Neurology.